Kyverna Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Kyverna Therapeutics generated cash of -$52,410,000, which is less than the previous year. Cash used in financing activities reached the amount of $58,118,000 last year. Net change in cash is therefore -$3,077,000.
Cash Flow
| 2022 | -36.11M | -14.09M | 11.88M |
|---|---|---|---|
| 2023 | -52.41M | -8.78M | 58.11M |
KYTX Cash Flow Statement (2022 – 2023)
| 2023 | 2022 | |
|---|---|---|
Cash at beginning of period | 38.28M | 76.61M |
Operating activities | ||
Net income | -60.36M | -28.89M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||
Depreciation and amortization | 1.70M | 1.05M |
Stock-based compensation expense | 2.22M | 929K |
| Deferred income tax benefit | 2.22M | 929K |
| Changes in operating assets and liabilities: | ||
Accounts receivable, net | 0 | 0 |
Inventories | 0 | 0 |
Accounts payable | 4.08M | 677K |
Cash generated by operating activities | -52.41M | -36.11M |
Investing activities | ||
Purchases Of Investments | -54.84M | -56.49M |
Investments In Property Plant And Equipment | -621K | -768K |
Acquisitions Net | 0 | 0 |
Cash generated by investing activities | -8.78M | -14.09M |
Financing activities | ||
Common Stock Issued | 0 | 12.12M |
Payments for dividends | 0 | 0 |
Repurchases of common stock | 0 | 0 |
Repayments of term debt | -781K | -249K |
Cash used in financing activities | 58.11M | 11.88M |
Net Change In Cash | -3.07M | -38.33M |
Cash at end of period | 35.21M | 38.28M |
| Data source |